The European Medicines Agency (EMA) Guideline on the Development and Manufacture of Synthetic Peptides, effective June 1st 2026, established the first dedicated European guidance for peptide therapeutics by addressing a long-recognized gap: synthetic peptides do not fit neatly within the traditional regulatory frameworks for small molecules or biologics. Indeed, the EMA states explicitly that synthetic peptides lie “at the interface of small molecules and proteins” and notes that important parts of the ICH framework such as ICH Q3A/B, Q6A/B, and ICH M7 do not fully cover peptide-specific quality, manufacturing, and analytical challenges that require more specificity than either framework has historically offered. This new guideline specifically addresses quality aspects not covered by broader guidelines.
Although the guideline covers manufacturing and pharmaceutical development, one of its most significant impacts is on analytical characterization. It raises expectations for demonstrating peptide identity, purity, and process understanding, bringing peptide analysis closer to the standards traditionally applied to biological medicines whilst maintaining the principles of chemical synthesis.
One of the most important aspects is the expectation that peptide characterization should rely on orthogonal analytical methods rather than a single chromatographic purity assay. Historically, many synthetic peptides were released based largely on reversed-phase HPLC purity and molecular weight confirmation. The new guideline makes it clear that this is no longer sufficient for complex therapeutic peptides. Instead, manufacturers should use complementary analytical techniques to demonstrate molecular identity, sequence integrity, and impurity profiles; both product-related and process-related.
Mass spectrometry has become central to this analytical strategy. High-resolution LC-MS is expected not only to confirm molecular weight but also to identify chemical modifications and degradation products. For larger peptides, intact mass measurements alone are unlikely to be adequate, with MS/MS fragmentation increasingly expected to confirm amino acid sequence and locate modifications. Consequently, LC-MS is evolving from a development tool into a core component of regulatory submissions.
The guideline also places great emphasis on understanding sequence-related impurities, recognizing that synthetic peptide manufacture can generate a wide range of closely related by-products. These include deletion and truncated sequences, amino acid substitutions, incomplete deprotection products, incomplete coupling products, racemized amino acids, oxidation products, and deamidated species. Rather than simply reporting an overall chromatographic purity value, manufacturers are expected to understand the origin of these impurities, demonstrate how they are controlled during synthesis and assess their potential impact on product quality.
This increased emphasis extends to impurity identification. Previously, chromatograms containing unidentified peaks were often considered acceptable, provided overall purity met specifications. Under the new guidance, significant impurities should be structurally characterized wherever feasible using techniques such as LC-MS/MS. Their formation should be linked to specific process steps or degradation pathways, enabling appropriate process controls and scientifically justified specifications. This represents a significant shift towards a Quality by Design (QbD) approach, where analytical characterization supports process understanding rather than simply batch release.
Our LC-MS/MS workflows structurally characterize sequence-related impurities and link them to root cause.
With characterization expectations, the EMA not only expects confirmation of primary structure but, where relevant, higher-order structure using suitable orthogonal analytical techniques. Mass spectrometry, amino acid analysis, NMR, circular dichroism, peptide mapping, and, in some cases, biological assays all appear in the recommended characterization toolbox. This is all scientifically appropriate. Although many peptides do not have meaningful or persistent higher-order structure, some do display relevant conformational features, oligomeric states, or aggregation tendencies that may affect biological performance.
The guideline also highlights the importance of stereochemical integrity. Racemization during peptide synthesis is a recognized challenge, particularly for certain amino acid residues. Sponsors are therefore expected to demonstrate that epimer formation is adequately controlled through process design or analytical evidence. Depending on the molecule, this may involve chiral chromatographic methods or development studies demonstrating that racemization remains negligible under the chosen manufacturing conditions.
For modified peptides, including cyclic peptides and lipidated or PEGylated analogs, analytical expectations are correspondingly higher. Characterization should establish not only peptide identity but also modification site, degree of substitution, linker integrity, and product heterogeneity. These molecules frequently require multiple complementary techniques, including LC-MS, size exclusion chromatography, and capillary electrophoresis, to provide a complete analytical picture.
Analytical methods are also expected to be stability-indicating. Methods should distinguish manufacturing-related impurities from degradation products and demonstrate the ability to detect changes arising during storage. Forced degradation studies should investigate likely degradation pathways, including oxidation, hydrolysis, and deamidation, ensuring that analytical procedures are capable of monitoring product stability throughout shelf life.
The guideline further encourages specifications that are based on process knowledge and clinical experience rather than generic acceptance criteria. Rather than relying solely on a specification such as "≥98% purity by HPLC," manufacturers are expected to justify impurity limits using manufacturing capability, toxicological assessment, and clinical batch data. This may lead to increased use of individual impurity specifications where specific process-related impurities are known to be critical.
Finally, the EMA emphasizes that analytical characterization should evolve throughout product development. Early-stage development should employ extensive analytical techniques to understand the molecule and identify potential critical quality attributes (CQAs). As manufacturing processes mature, analytical data should be used to establish robust control strategies and define clinically relevant specifications for commercial manufacture. This lifecycle approach aligns peptide development with modern pharmaceutical quality principles and reinforces the role of analytical science in demonstrating product consistency.
Overall, the EMA's 2026 guideline represents a significant evolution in regulatory expectations for synthetic peptides. It shifts the focus from demonstrating chromatographic purity alone to achieving a comprehensive understanding of molecular identity, impurity profiles, and manufacturing processes. For developers of therapeutic peptides including GLP-1 analogs, cyclic peptides, and other complex synthetic peptides, this will require broader analytical toolkits, greater reliance on high-resolution LC-MS/MS, and more extensive impurity characterization than has historically been expected. Although these requirements will increase analytical development effort, they should ultimately lead to more robust control strategies, improved product understanding, and greater confidence in peptide quality throughout the product lifecycle.
